The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients (clinicaltrials.gov) - Jun 16, 2026 - P=N/A | N=105 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2026 ➔ Jul 2027
Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Cytomegalovirus Infection • Transplantation • HLA-B
|